サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1344307

ナノテクノロジードラッグデリバリー市場：製剤別、用途別：世界の機会分析と産業予測、2023-2032年

Nanotechnology Drug Delivery Market By Formulation, By Application : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日: | 発行: Allied Market Research | ページ情報: 英文 245 Pages | 納期: 2～3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
ナノテクノロジードラッグデリバリー市場：製剤別、用途別：世界の機会分析と産業予測、2023-2032年
出版日: 2023年06月01日
発行: Allied Market Research
ページ情報: 英文 245 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ナノテクノロジードラッグデリバリー市場は2022年に875億米ドルと評価され、2023年から2032年にかけてCAGR 9.1％で成長し、2032年には2,095億米ドルに達すると推定されています。

ナノテクノロジーは、標的治療、薬効強化、患者の転帰改善といった課題を克服する革新的なソリューションを提供することで、ドラッグデリバリーの分野に革命をもたらしました。ナノテクノロジードラッグデリバリー市場は著しい成長を遂げており、医療の将来にとって計り知れない可能性を秘めています。ナノ粒子、ナノエマルジョン、ナノキャリアは、ドラッグデリバリーシステムに使用されるナノテクノロジーの主要な構成要素の一部です。これらのナノスケール構造は、高い表面積対体積比や、治療薬をカプセル化して体内の特定の標的部位に送達する能力など、ユニークな物理化学的特性を有しています。

Nanotechnology Drug Delivery Market-IMG1

ナノテクノロジードラッグデリバリー市場を牽引するのは、慢性疾患の有病率の上昇とナノテクノロジーの進歩です。慢性疾患の増加は、ナノテクノロジードラッグデリバリー市場の主要な促進要因として浮上しています。がん、糖尿病、心血管疾患、呼吸器疾患などの慢性疾患は、世界的に重大な健康課題をもたらし続けています。国際糖尿病連合によると、2021年には約5億3,700万人が糖尿病を患っていると推定されています。さらに同出典によると、糖尿病患者の総数は2030年までに6億4,300万人、2045年までに7億8,300万人に増加すると予測されています。例えば、モナシュ大学、RMIT大学、メルボルン大学、ベイカー研究所の研究者たちは、現在のインスリンにはないグルコースに反応するシステムを開発しました。

前臨床研究では、体にとって本当に必要なときだけインスリンを放出する優れた人工膵臓システムが設計され、その結果、血糖値をより確実に調節できるようになっています。この革新的なナノ糖質プラットフォームは、グルコースレベルに反応する迅速かつ一貫したインスリン分泌を促進し、持続時間とインテリジェンスの点で他のシステムを凌駕しました。ドラッグデリバリーの精度、ターゲティング、個別化医療を強化するナノテクノロジーのユニークな能力は、慢性疾患管理に関連する課題に対処する有望なソリューションとして位置づけられています。このように、慢性疾患の有病率の増加は、ナノテクノロジードラッグデリバリー市場の成長を支える主要な原動力となっています。

さらに、ナノ医薬品の技術的進歩は、ナノテクノロジードラッグデリバリー市場の成長に重要な役割を果たすと期待されています。従来のドラッグデリバリーシステム（DDS）の限界から、ナノキャリアの人気が著しく高まっています。例えば、アリゾナ州立大学の科学者たちは、さまざまな形に変形する能力からそのように呼ばれる「折り紙ナノロボット」を作成しました。これは、血液凝固酵素でコーティングされた平らな合成DNAシートで構成されています。血流に注入されると、ナノスケールのDNAシートは腫瘍細胞を見つけ、その表面に結合し、血液凝固酵素を導入し、腫瘍細胞の生存に必要な血液供給を効果的に奪うように設計されています。

この小さなロボットは、がん治療の課題である、がん細胞を根絶する一方で、近くの健康な組織へのダメージを最小限に抑えることに取り組んでいます。しかし、製造の複雑さが市場成長の抑制要因になる可能性があります。一方、研究活動を奨励するための資金援助などの政府の取り組みは、ナノテクノロジードラッグデリバリー市場の成長機会として役立つと期待されています。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場の定義と範囲
  • 主な調査結果
    • 影響要因
    • 主な投資機会
  • ポーターのファイブフォース分析
  • 市場力学
    • 促進要因
      • 慢性疾患の増加
      • ナノテクノロジーの進歩
    • 抑制要因
      • 製造の複雑さ
    • 機会
      • 政府の取り組み
  • COVID-19市場への影響分析

第4章 ナノテクノロジードラッグデリバリー市場：製剤別

  • 概要
  • 脂質ベースのナノメディシン
  • ポリマーベースのナノメディシン
  • ナノ結晶
  • その他

第5章 ナノテクノロジードラッグデリバリー市場：用途別

  • 概要
  • オンコロジーおよび血液学
  • 感染症
  • 整形外科
  • 神経学
  • 泌尿器科
  • 免疫学
  • その他

第6章 ナノテクノロジードラッグデリバリー市場：地域別

  • 概要
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • その他欧州
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • オーストラリア
    • 韓国
    • その他アジア太平洋地域
  • ラテンアメリカ・中東・アフリカ
    • ブラジル
    • サウジアラビア
    • 南アフリカ
    • その他の地域

第7章 競合情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10社の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • 主要企業のポジショニング、2022年

第8章 企業プロファイル

  • Abbvie Inc
  • Pfizer Ltd
  • AstraZeneca plc
  • Johnson & Johnson
  • Amgen Inc.
  • Merck KGaA
  • Nanobiotix SA
  • Novartis AG
  • Teva Pharmaceutical Industries Limited
  • Bristol-Myers Squibb Company
図表

LIST OF TABLES

  • TABLE 01. GLOBAL NANOTECHNOLOGY DRUG DELIVERY MARKET, BY FORMULATION, 2022-2032 ($MILLION)
  • TABLE 02. NANOTECHNOLOGY DRUG DELIVERY MARKET FOR LIPID-BASED NANOMEDICINE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. NANOTECHNOLOGY DRUG DELIVERY MARKET FOR POLYMER-BASED NANOMEDICINE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. NANOTECHNOLOGY DRUG DELIVERY MARKET FOR NANOCRYSTALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. NANOTECHNOLOGY DRUG DELIVERY MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 06. GLOBAL NANOTECHNOLOGY DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 07. NANOTECHNOLOGY DRUG DELIVERY MARKET FOR ONCOLOGY AND HEMATOLOGY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. NANOTECHNOLOGY DRUG DELIVERY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 09. NANOTECHNOLOGY DRUG DELIVERY MARKET FOR ORTHOPEDICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. NANOTECHNOLOGY DRUG DELIVERY MARKET FOR NEUROLOGY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. NANOTECHNOLOGY DRUG DELIVERY MARKET FOR UROLOGY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. NANOTECHNOLOGY DRUG DELIVERY MARKET FOR IMMUNOLOGY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. NANOTECHNOLOGY DRUG DELIVERY MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. NANOTECHNOLOGY DRUG DELIVERY MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. NORTH AMERICA NANOTECHNOLOGY DRUG DELIVERY MARKET, BY FORMULATION, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA NANOTECHNOLOGY DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA NANOTECHNOLOGY DRUG DELIVERY MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 18. U.S. NANOTECHNOLOGY DRUG DELIVERY MARKET, BY FORMULATION, 2022-2032 ($MILLION)
  • TABLE 19. U.S. NANOTECHNOLOGY DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 20. CANADA NANOTECHNOLOGY DRUG DELIVERY MARKET, BY FORMULATION, 2022-2032 ($MILLION)
  • TABLE 21. CANADA NANOTECHNOLOGY DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 22. MEXICO NANOTECHNOLOGY DRUG DELIVERY MARKET, BY FORMULATION, 2022-2032 ($MILLION)
  • TABLE 23. MEXICO NANOTECHNOLOGY DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 24. EUROPE NANOTECHNOLOGY DRUG DELIVERY MARKET, BY FORMULATION, 2022-2032 ($MILLION)
  • TABLE 25. EUROPE NANOTECHNOLOGY DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 26. EUROPE NANOTECHNOLOGY DRUG DELIVERY MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 27. GERMANY NANOTECHNOLOGY DRUG DELIVERY MARKET, BY FORMULATION, 2022-2032 ($MILLION)
  • TABLE 28. GERMANY NANOTECHNOLOGY DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 29. FRANCE NANOTECHNOLOGY DRUG DELIVERY MARKET, BY FORMULATION, 2022-2032 ($MILLION)
  • TABLE 30. FRANCE NANOTECHNOLOGY DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 31. UK NANOTECHNOLOGY DRUG DELIVERY MARKET, BY FORMULATION, 2022-2032 ($MILLION)
  • TABLE 32. UK NANOTECHNOLOGY DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 33. ITALY NANOTECHNOLOGY DRUG DELIVERY MARKET, BY FORMULATION, 2022-2032 ($MILLION)
  • TABLE 34. ITALY NANOTECHNOLOGY DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 35. SPAIN NANOTECHNOLOGY DRUG DELIVERY MARKET, BY FORMULATION, 2022-2032 ($MILLION)
  • TABLE 36. SPAIN NANOTECHNOLOGY DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 37. REST OF EUROPE NANOTECHNOLOGY DRUG DELIVERY MARKET, BY FORMULATION, 2022-2032 ($MILLION)
  • TABLE 38. REST OF EUROPE NANOTECHNOLOGY DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 39. ASIA-PACIFIC NANOTECHNOLOGY DRUG DELIVERY MARKET, BY FORMULATION, 2022-2032 ($MILLION)
  • TABLE 40. ASIA-PACIFIC NANOTECHNOLOGY DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 41. ASIA-PACIFIC NANOTECHNOLOGY DRUG DELIVERY MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 42. CHINA NANOTECHNOLOGY DRUG DELIVERY MARKET, BY FORMULATION, 2022-2032 ($MILLION)
  • TABLE 43. CHINA NANOTECHNOLOGY DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 44. JAPAN NANOTECHNOLOGY DRUG DELIVERY MARKET, BY FORMULATION, 2022-2032 ($MILLION)
  • TABLE 45. JAPAN NANOTECHNOLOGY DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 46. INDIA NANOTECHNOLOGY DRUG DELIVERY MARKET, BY FORMULATION, 2022-2032 ($MILLION)
  • TABLE 47. INDIA NANOTECHNOLOGY DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 48. AUSTRALIA NANOTECHNOLOGY DRUG DELIVERY MARKET, BY FORMULATION, 2022-2032 ($MILLION)
  • TABLE 49. AUSTRALIA NANOTECHNOLOGY DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 50. SOUTH KOREA NANOTECHNOLOGY DRUG DELIVERY MARKET, BY FORMULATION, 2022-2032 ($MILLION)
  • TABLE 51. SOUTH KOREA NANOTECHNOLOGY DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 52. REST OF ASIA-PACIFIC NANOTECHNOLOGY DRUG DELIVERY MARKET, BY FORMULATION, 2022-2032 ($MILLION)
  • TABLE 53. REST OF ASIA-PACIFIC NANOTECHNOLOGY DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 54. LAMEA NANOTECHNOLOGY DRUG DELIVERY MARKET, BY FORMULATION, 2022-2032 ($MILLION)
  • TABLE 55. LAMEA NANOTECHNOLOGY DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 56. LAMEA NANOTECHNOLOGY DRUG DELIVERY MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 57. BRAZIL NANOTECHNOLOGY DRUG DELIVERY MARKET, BY FORMULATION, 2022-2032 ($MILLION)
  • TABLE 58. BRAZIL NANOTECHNOLOGY DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 59. SAUDI ARABIA NANOTECHNOLOGY DRUG DELIVERY MARKET, BY FORMULATION, 2022-2032 ($MILLION)
  • TABLE 60. SAUDI ARABIA NANOTECHNOLOGY DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 61. SOUTH AFRICA NANOTECHNOLOGY DRUG DELIVERY MARKET, BY FORMULATION, 2022-2032 ($MILLION)
  • TABLE 62. SOUTH AFRICA NANOTECHNOLOGY DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 63. REST OF LAMEA NANOTECHNOLOGY DRUG DELIVERY MARKET, BY FORMULATION, 2022-2032 ($MILLION)
  • TABLE 64. REST OF LAMEA NANOTECHNOLOGY DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 65. ABBVIE INC: KEY EXECUTIVES
  • TABLE 66. ABBVIE INC: COMPANY SNAPSHOT
  • TABLE 67. ABBVIE INC: PRODUCT SEGMENTS
  • TABLE 68. ABBVIE INC: PRODUCT PORTFOLIO
  • TABLE 69. PFIZER LTD: KEY EXECUTIVES
  • TABLE 70. PFIZER LTD: COMPANY SNAPSHOT
  • TABLE 71. PFIZER LTD: PRODUCT SEGMENTS
  • TABLE 72. PFIZER LTD: PRODUCT PORTFOLIO
  • TABLE 73. PFIZER LTD: KEY STRATERGIES
  • TABLE 74. ASTRAZENECA PLC: KEY EXECUTIVES
  • TABLE 75. ASTRAZENECA PLC: COMPANY SNAPSHOT
  • TABLE 76. ASTRAZENECA PLC: PRODUCT SEGMENTS
  • TABLE 77. ASTRAZENECA PLC: PRODUCT PORTFOLIO
  • TABLE 78. JOHNSON & JOHNSON: KEY EXECUTIVES
  • TABLE 79. JOHNSON & JOHNSON: COMPANY SNAPSHOT
  • TABLE 80. JOHNSON & JOHNSON: PRODUCT SEGMENTS
  • TABLE 81. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
  • TABLE 82. AMGEN INC.: KEY EXECUTIVES
  • TABLE 83. AMGEN INC.: COMPANY SNAPSHOT
  • TABLE 84. AMGEN INC.: PRODUCT SEGMENTS
  • TABLE 85. AMGEN INC.: PRODUCT PORTFOLIO
  • TABLE 86. MERCK KGAA: KEY EXECUTIVES
  • TABLE 87. MERCK KGAA: COMPANY SNAPSHOT
  • TABLE 88. MERCK KGAA: PRODUCT SEGMENTS
  • TABLE 89. MERCK KGAA: PRODUCT PORTFOLIO
  • TABLE 90. NANOBIOTIX SA: KEY EXECUTIVES
  • TABLE 91. NANOBIOTIX SA: COMPANY SNAPSHOT
  • TABLE 92. NANOBIOTIX SA: PRODUCT SEGMENTS
  • TABLE 93. NANOBIOTIX SA: PRODUCT PORTFOLIO
  • TABLE 94. NANOBIOTIX SA: KEY STRATERGIES
  • TABLE 95. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 96. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 97. NOVARTIS AG: PRODUCT SEGMENTS
  • TABLE 98. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 99. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
  • TABLE 100. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
  • TABLE 101. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS
  • TABLE 102. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
  • TABLE 103. BRISTOL-MYERS SQUIBB COMPANY: KEY EXECUTIVES
  • TABLE 104. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
  • TABLE 105. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT SEGMENTS
  • TABLE 106. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. NANOTECHNOLOGY DRUG DELIVERY MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF NANOTECHNOLOGY DRUG DELIVERY MARKET, 2022-2032
  • FIGURE 03. TOP INVESTMENT POCKETS IN NANOTECHNOLOGY DRUG DELIVERY MARKET (2023-2032)
  • FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. LOW THREAT OF NEW ENTRANTS
  • FIGURE 06. LOW THREAT OF SUBSTITUTES
  • FIGURE 07. LOW INTENSITY OF RIVALRY
  • FIGURE 08. LOW BARGAINING POWER OF BUYERS
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALNANOTECHNOLOGY DRUG DELIVERY MARKET
  • FIGURE 09. NANOTECHNOLOGY DRUG DELIVERY MARKET, BY FORMULATION, 2022(%)
  • FIGURE 10. COMPARATIVE SHARE ANALYSIS OF NANOTECHNOLOGY DRUG DELIVERY MARKET FOR LIPID-BASED NANOMEDICINE, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF NANOTECHNOLOGY DRUG DELIVERY MARKET FOR POLYMER-BASED NANOMEDICINE, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF NANOTECHNOLOGY DRUG DELIVERY MARKET FOR NANOCRYSTALS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF NANOTECHNOLOGY DRUG DELIVERY MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. NANOTECHNOLOGY DRUG DELIVERY MARKET, BY APPLICATION, 2022(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF NANOTECHNOLOGY DRUG DELIVERY MARKET FOR ONCOLOGY AND HEMATOLOGY, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF NANOTECHNOLOGY DRUG DELIVERY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF NANOTECHNOLOGY DRUG DELIVERY MARKET FOR ORTHOPEDICS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF NANOTECHNOLOGY DRUG DELIVERY MARKET FOR NEUROLOGY, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF NANOTECHNOLOGY DRUG DELIVERY MARKET FOR UROLOGY, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF NANOTECHNOLOGY DRUG DELIVERY MARKET FOR IMMUNOLOGY, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF NANOTECHNOLOGY DRUG DELIVERY MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 22. NANOTECHNOLOGY DRUG DELIVERY MARKET BY REGION, 2022
  • FIGURE 23. U.S. NANOTECHNOLOGY DRUG DELIVERY MARKET, 2022-2032 ($MILLION)
  • FIGURE 24. CANADA NANOTECHNOLOGY DRUG DELIVERY MARKET, 2022-2032 ($MILLION)
  • FIGURE 25. MEXICO NANOTECHNOLOGY DRUG DELIVERY MARKET, 2022-2032 ($MILLION)
  • FIGURE 26. GERMANY NANOTECHNOLOGY DRUG DELIVERY MARKET, 2022-2032 ($MILLION)
  • FIGURE 27. FRANCE NANOTECHNOLOGY DRUG DELIVERY MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. UK NANOTECHNOLOGY DRUG DELIVERY MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. ITALY NANOTECHNOLOGY DRUG DELIVERY MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. SPAIN NANOTECHNOLOGY DRUG DELIVERY MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. REST OF EUROPE NANOTECHNOLOGY DRUG DELIVERY MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. CHINA NANOTECHNOLOGY DRUG DELIVERY MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. JAPAN NANOTECHNOLOGY DRUG DELIVERY MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. INDIA NANOTECHNOLOGY DRUG DELIVERY MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. AUSTRALIA NANOTECHNOLOGY DRUG DELIVERY MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. SOUTH KOREA NANOTECHNOLOGY DRUG DELIVERY MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. REST OF ASIA-PACIFIC NANOTECHNOLOGY DRUG DELIVERY MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. BRAZIL NANOTECHNOLOGY DRUG DELIVERY MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. SAUDI ARABIA NANOTECHNOLOGY DRUG DELIVERY MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. SOUTH AFRICA NANOTECHNOLOGY DRUG DELIVERY MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. REST OF LAMEA NANOTECHNOLOGY DRUG DELIVERY MARKET, 2022-2032 ($MILLION)
  • FIGURE 42. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 43. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 44. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 45. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 46. COMPETITIVE DASHBOARD
  • FIGURE 47. COMPETITIVE HEATMAP: NANOTECHNOLOGY DRUG DELIVERY MARKET
  • FIGURE 48. TOP PLAYER POSITIONING, 2022
  • FIGURE 49. ABBVIE INC: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 50. ABBVIE INC: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 51. ABBVIE INC: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 52. PFIZER LTD: SALES REVENUE, 2020-2022 ($MILLION)
  • FIGURE 53. PFIZER LTD: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 54. PFIZER LTD: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 55. ASTRAZENECA PLC: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 56. JOHNSON & JOHNSON: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 57. JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 58. JOHNSON & JOHNSON: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 59. AMGEN INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 60. AMGEN INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 61. AMGEN INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 62. MERCK KGAA: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 63. MERCK KGAA: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 64. MERCK KGAA: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 65. NANOBIOTIX SA: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 66. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 67. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 68. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 69. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 70. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 71. BRISTOL-MYERS SQUIBB COMPANY: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 72. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE BY REGION, 2022 (%)
目次
Product Code: A10459

According to a new report published by Allied Market Research, titled, "Nanotechnology Drug Delivery Market," The nanotechnology drug delivery market was valued at $87.5 billion in 2022, and is estimated to reach $209.5 billion by 2032, growing at a CAGR of 9.1% from 2023 to 2032. Nanotechnology has revolutionized the field of drug delivery by offering innovative solutions to overcome challenges in targeted therapy, enhanced drug efficacy, and improved patient outcomes. The nanotechnology-based drug delivery market has witnessed significant growth and holds immense potential for the future of medicine. Nanoparticles, nano emulsions, and nanocarriers are some of the key components of nanotechnology used in drug delivery systems. These nanoscale structures possess unique physicochemical properties, such as a high surface area-to-volume ratio and the ability to encapsulate and deliver therapeutic agents to specific target sites in the body.

Nanotechnology Drug Delivery Market - IMG1

The nanotechnology drug delivery market is driven by rise in prevalence of chronic diseases, and advancements in nanotechnology. The rise in prevalence of chronic diseases has emerged as a major driver for the nanotechnology drug delivery market. Chronic diseases, such as cancer, diabetes, cardiovascular diseases, and respiratory disorders, continue to pose significant health challenges globally. According to International Diabetes Federation, in 2021, it was estimated that approximately 537 million people were living with diabetes. Furthermore, according to the same source, the total number of people living with diabetes is projected to rise to 643 million by 2030 and 783 million by 2045. For instance, researchers from Monash University, RMIT University, The University of Melbourne and the Baker Institute developed a system that responds to glucose, which current insulin does not.

The preclinical study engineered a superior artificial pancreas system to release insulin only when it is genuinely required by the body, resulting in a more dependable regulation of blood glucose levels. This innovative nano sugar platform facilitated prompt and consistent insulin delivery that responded to glucose levels, surpassing other systems in terms of duration and intelligence. The unique capabilities of nanotechnology in enhancing drug delivery precision, targeting, and personalized medicine have positioned it as a promising solution to address the challenges associated with chronic disease management. Thus, the rise in prevalence of chronic diseases has become a key driving force behind the growth of the nanotechnology drug delivery market.

Furthermore, technological advancements in nanomedicines are expected to play a significant role in the growth of the nanotechnology drug delivery market. The limitations of traditional drug delivery systems (DDSs) have led to a significant rise in the popularity of nanocarriers. For instance, scientists at Arizona State University have created an "origami nanorobot" known as such due to its ability to transform into different forms. It comprises a flat synthetic DNA sheet coated with a blood-clotting enzyme. Once injected into the bloodstream, the nanoscale DNA sheet is designed to locate tumor cells, bind to their surface, and introduce the blood-clotting enzyme, effectively depriving the tumor cell of the necessary blood supply for its survival.

This tiny robot addresses a challenging aspect of cancer treatment, which involves eradicating cancer cells while minimizing damage to nearby healthy tissue. However, manufacturing complexities might act as a restraint for the growth of the market. On the other hand, government initiatives such as funding to encourage research activities are expected to serve as growth opportunity in the nanotechnology drug delivery market. The nanotechnology drug delivery market is segmented on the basis of formulation, application, and region. formulation, the market is categorized into lipid-based nanomedicine, polymer-based nanomedicine, nanocrystals, and others.

The others include inorganic nanoparticles, protein-based nanoparticles, and micelles. On the basis of application, the market is categorized into oncology & hematology, infectious diseases, orthopedics, neurology, urology, immunology, and others. The others include gastrointestinal, inflammatory, endocrine, integumentary ophthalmology, and cardiology.

On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA). The key players that operate in the global nanotechnology drug delivery market are AbbVie Inc, Pfizer Inc., AstraZeneca plc, Johnson & Johnson, Amgen Inc, Merck KGaA, Nanobiotix SA, Novartis AG, Bristol-Myers Squibb Company, and Teva Pharmaceutical Industries Limited.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the nanotechnology drug delivery market analysis from 2022 to 2032 to identify the prevailing nanotechnology drug delivery market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the nanotechnology drug delivery market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global nanotechnology drug delivery market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Formulation

  • Lipid-based nanomedicine
  • Polymer-based nanomedicine
  • Nanocrystals
  • Others

By Application

  • Oncology and Hematology
  • Infectious diseases
  • Orthopedics
  • Neurology
  • Urology
  • Immunology
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Abbvie Inc
    • Amgen Inc.
    • AstraZeneca plc
    • Bristol-Myers Squibb Company
    • Johnson & Johnson
    • Merck KGaA
    • Nanobiotix SA
    • Novartis AG
    • Pfizer Ltd
    • Teva Pharmaceutical Industries Limited

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Low bargaining power of suppliers
    • 3.3.2. Low threat of new entrants
    • 3.3.3. Low threat of substitutes
    • 3.3.4. Low intensity of rivalry
    • 3.3.5. Low bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Rise in prevalence of chronic diseases.
      • 3.4.1.2. Advancement in nanotechnology
    • 3.4.2. Restraints
      • 3.4.2.1. Manufacturing Complexities
    • 3.4.3. Opportunities
      • 3.4.3.1. Government initiatives
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: NANOTECHNOLOGY DRUG DELIVERY MARKET, BY FORMULATION

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Lipid-based nanomedicine
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Polymer-based nanomedicine
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Nanocrystals
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country
  • 4.5. Others
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market share analysis by country

CHAPTER 5: NANOTECHNOLOGY DRUG DELIVERY MARKET, BY APPLICATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Oncology and Hematology
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Infectious diseases
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Orthopedics
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country
  • 5.5. Neurology
    • 5.5.1. Key market trends, growth factors and opportunities
    • 5.5.2. Market size and forecast, by region
    • 5.5.3. Market share analysis by country
  • 5.6. Urology
    • 5.6.1. Key market trends, growth factors and opportunities
    • 5.6.2. Market size and forecast, by region
    • 5.6.3. Market share analysis by country
  • 5.7. Immunology
    • 5.7.1. Key market trends, growth factors and opportunities
    • 5.7.2. Market size and forecast, by region
    • 5.7.3. Market share analysis by country
  • 5.8. Others
    • 5.8.1. Key market trends, growth factors and opportunities
    • 5.8.2. Market size and forecast, by region
    • 5.8.3. Market share analysis by country

CHAPTER 6: NANOTECHNOLOGY DRUG DELIVERY MARKET, BY REGION

  • 6.1. Overview
    • 6.1.1. Market size and forecast By Region
  • 6.2. North America
    • 6.2.1. Key trends and opportunities
    • 6.2.2. Market size and forecast, by Formulation
    • 6.2.3. Market size and forecast, by Application
    • 6.2.4. Market size and forecast, by country
      • 6.2.4.1. U.S.
      • 6.2.4.1.1. Key market trends, growth factors and opportunities
      • 6.2.4.1.2. Market size and forecast, by Formulation
      • 6.2.4.1.3. Market size and forecast, by Application
      • 6.2.4.2. Canada
      • 6.2.4.2.1. Key market trends, growth factors and opportunities
      • 6.2.4.2.2. Market size and forecast, by Formulation
      • 6.2.4.2.3. Market size and forecast, by Application
      • 6.2.4.3. Mexico
      • 6.2.4.3.1. Key market trends, growth factors and opportunities
      • 6.2.4.3.2. Market size and forecast, by Formulation
      • 6.2.4.3.3. Market size and forecast, by Application
  • 6.3. Europe
    • 6.3.1. Key trends and opportunities
    • 6.3.2. Market size and forecast, by Formulation
    • 6.3.3. Market size and forecast, by Application
    • 6.3.4. Market size and forecast, by country
      • 6.3.4.1. Germany
      • 6.3.4.1.1. Key market trends, growth factors and opportunities
      • 6.3.4.1.2. Market size and forecast, by Formulation
      • 6.3.4.1.3. Market size and forecast, by Application
      • 6.3.4.2. France
      • 6.3.4.2.1. Key market trends, growth factors and opportunities
      • 6.3.4.2.2. Market size and forecast, by Formulation
      • 6.3.4.2.3. Market size and forecast, by Application
      • 6.3.4.3. UK
      • 6.3.4.3.1. Key market trends, growth factors and opportunities
      • 6.3.4.3.2. Market size and forecast, by Formulation
      • 6.3.4.3.3. Market size and forecast, by Application
      • 6.3.4.4. Italy
      • 6.3.4.4.1. Key market trends, growth factors and opportunities
      • 6.3.4.4.2. Market size and forecast, by Formulation
      • 6.3.4.4.3. Market size and forecast, by Application
      • 6.3.4.5. Spain
      • 6.3.4.5.1. Key market trends, growth factors and opportunities
      • 6.3.4.5.2. Market size and forecast, by Formulation
      • 6.3.4.5.3. Market size and forecast, by Application
      • 6.3.4.6. Rest of Europe
      • 6.3.4.6.1. Key market trends, growth factors and opportunities
      • 6.3.4.6.2. Market size and forecast, by Formulation
      • 6.3.4.6.3. Market size and forecast, by Application
  • 6.4. Asia-Pacific
    • 6.4.1. Key trends and opportunities
    • 6.4.2. Market size and forecast, by Formulation
    • 6.4.3. Market size and forecast, by Application
    • 6.4.4. Market size and forecast, by country
      • 6.4.4.1. China
      • 6.4.4.1.1. Key market trends, growth factors and opportunities
      • 6.4.4.1.2. Market size and forecast, by Formulation
      • 6.4.4.1.3. Market size and forecast, by Application
      • 6.4.4.2. Japan
      • 6.4.4.2.1. Key market trends, growth factors and opportunities
      • 6.4.4.2.2. Market size and forecast, by Formulation
      • 6.4.4.2.3. Market size and forecast, by Application
      • 6.4.4.3. India
      • 6.4.4.3.1. Key market trends, growth factors and opportunities
      • 6.4.4.3.2. Market size and forecast, by Formulation
      • 6.4.4.3.3. Market size and forecast, by Application
      • 6.4.4.4. Australia
      • 6.4.4.4.1. Key market trends, growth factors and opportunities
      • 6.4.4.4.2. Market size and forecast, by Formulation
      • 6.4.4.4.3. Market size and forecast, by Application
      • 6.4.4.5. South Korea
      • 6.4.4.5.1. Key market trends, growth factors and opportunities
      • 6.4.4.5.2. Market size and forecast, by Formulation
      • 6.4.4.5.3. Market size and forecast, by Application
      • 6.4.4.6. Rest of Asia-Pacific
      • 6.4.4.6.1. Key market trends, growth factors and opportunities
      • 6.4.4.6.2. Market size and forecast, by Formulation
      • 6.4.4.6.3. Market size and forecast, by Application
  • 6.5. LAMEA
    • 6.5.1. Key trends and opportunities
    • 6.5.2. Market size and forecast, by Formulation
    • 6.5.3. Market size and forecast, by Application
    • 6.5.4. Market size and forecast, by country
      • 6.5.4.1. Brazil
      • 6.5.4.1.1. Key market trends, growth factors and opportunities
      • 6.5.4.1.2. Market size and forecast, by Formulation
      • 6.5.4.1.3. Market size and forecast, by Application
      • 6.5.4.2. Saudi Arabia
      • 6.5.4.2.1. Key market trends, growth factors and opportunities
      • 6.5.4.2.2. Market size and forecast, by Formulation
      • 6.5.4.2.3. Market size and forecast, by Application
      • 6.5.4.3. South Africa
      • 6.5.4.3.1. Key market trends, growth factors and opportunities
      • 6.5.4.3.2. Market size and forecast, by Formulation
      • 6.5.4.3.3. Market size and forecast, by Application
      • 6.5.4.4. Rest of LAMEA
      • 6.5.4.4.1. Key market trends, growth factors and opportunities
      • 6.5.4.4.2. Market size and forecast, by Formulation
      • 6.5.4.4.3. Market size and forecast, by Application

CHAPTER 7: COMPETITIVE LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top winning strategies
  • 7.3. Product Mapping of Top 10 Player
  • 7.4. Competitive Dashboard
  • 7.5. Competitive Heatmap
  • 7.6. Top player positioning, 2022

CHAPTER 8: COMPANY PROFILES

  • 8.1. Abbvie Inc
    • 8.1.1. Company overview
    • 8.1.2. Key Executives
    • 8.1.3. Company snapshot
    • 8.1.4. Operating business segments
    • 8.1.5. Product portfolio
    • 8.1.6. Business performance
  • 8.2. Pfizer Ltd
    • 8.2.1. Company overview
    • 8.2.2. Key Executives
    • 8.2.3. Company snapshot
    • 8.2.4. Operating business segments
    • 8.2.5. Product portfolio
    • 8.2.6. Business performance
    • 8.2.7. Key strategic moves and developments
  • 8.3. AstraZeneca plc
    • 8.3.1. Company overview
    • 8.3.2. Key Executives
    • 8.3.3. Company snapshot
    • 8.3.4. Operating business segments
    • 8.3.5. Product portfolio
    • 8.3.6. Business performance
  • 8.4. Johnson & Johnson
    • 8.4.1. Company overview
    • 8.4.2. Key Executives
    • 8.4.3. Company snapshot
    • 8.4.4. Operating business segments
    • 8.4.5. Product portfolio
    • 8.4.6. Business performance
  • 8.5. Amgen Inc.
    • 8.5.1. Company overview
    • 8.5.2. Key Executives
    • 8.5.3. Company snapshot
    • 8.5.4. Operating business segments
    • 8.5.5. Product portfolio
    • 8.5.6. Business performance
  • 8.6. Merck KGaA
    • 8.6.1. Company overview
    • 8.6.2. Key Executives
    • 8.6.3. Company snapshot
    • 8.6.4. Operating business segments
    • 8.6.5. Product portfolio
    • 8.6.6. Business performance
  • 8.7. Nanobiotix SA
    • 8.7.1. Company overview
    • 8.7.2. Key Executives
    • 8.7.3. Company snapshot
    • 8.7.4. Operating business segments
    • 8.7.5. Product portfolio
    • 8.7.6. Business performance
    • 8.7.7. Key strategic moves and developments
  • 8.8. Novartis AG
    • 8.8.1. Company overview
    • 8.8.2. Key Executives
    • 8.8.3. Company snapshot
    • 8.8.4. Operating business segments
    • 8.8.5. Product portfolio
    • 8.8.6. Business performance
  • 8.9. Teva Pharmaceutical Industries Limited
    • 8.9.1. Company overview
    • 8.9.2. Key Executives
    • 8.9.3. Company snapshot
    • 8.9.4. Operating business segments
    • 8.9.5. Product portfolio
    • 8.9.6. Business performance
  • 8.10. Bristol-Myers Squibb Company
    • 8.10.1. Company overview
    • 8.10.2. Key Executives
    • 8.10.3. Company snapshot
    • 8.10.4. Operating business segments
    • 8.10.5. Product portfolio
    • 8.10.6. Business performance